Who are Ketoprofen and Omeprazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Surgery with Naproxen and Esomeprazole, Diclofenac + Omeprazole, FDC KETOPROFEN+OMEPRAZOLE, Nimesulide + Pantoprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketoprofen-and-omeprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ketoprofen and Omeprazole — Competitive Intelligence Brief

Ketoprofen and Omeprazole (Ketoprofen and Omeprazole) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + Proton pump inhibitor combination. Area: Rheumatology / Pain Management / Gastroenterology.

marketed NSAID + Proton pump inhibitor combination COX-1/COX-2 (ketoprofen); H+/K+-ATPase (omeprazole) Rheumatology / Pain Management / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ketoprofen and Omeprazole (Ketoprofen and Omeprazole) — Luis Fernando Simoneti. Ketoprofen inhibits prostaglandin synthesis via COX inhibition to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ketoprofen and Omeprazole TARGET	Ketoprofen and Omeprazole	Luis Fernando Simoneti	marketed	NSAID + Proton pump inhibitor combination	COX-1/COX-2 (ketoprofen); H+/K+-ATPase (omeprazole)
Surgery with Naproxen and Esomeprazole	Surgery with Naproxen and Esomeprazole	Giovana Maria Weckwerth	marketed	NSAID + Proton pump inhibitor combination	COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
Diclofenac + Omeprazole	Diclofenac + Omeprazole	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	NSAID + Proton pump inhibitor combination	COX-1/COX-2 (diclofenac); H+/K+-ATPase (omeprazole)
FDC KETOPROFEN+OMEPRAZOLE	FDC KETOPROFEN+OMEPRAZOLE	Sanofi	phase 3	NSAID + Proton pump inhibitor combination	COX-1/COX-2 (ketoprofen); H+/K+-ATPase (omeprazole)
Nimesulide + Pantoprazole	Nimesulide + Pantoprazole	EMS	phase 3	NSAID + Proton pump inhibitor combination	COX-2 enzyme (nimesulide); H+/K+-ATPase (pantoprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + Proton pump inhibitor combination class)

EMS · 1 drug in this class
Giovana Maria Weckwerth · 1 drug in this class
Luis Fernando Simoneti · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketoprofen and Omeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/ketoprofen-and-omeprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab